Zevalin On Track For Medicare ASP-Based Reimbursement In 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
Change to average sales price based payment for Cell Therapeutics’ radioimmunotherapy could help boost use in community oncology centers.